Table 1. Characteristics of the included trials.
| Author | Year | Sample size | Age (years) | Evaluation tools | Symptom duration | NIH-CPSI | Catastrophizing scores | Percentage of psychosociala | Percentage of catastrophizing (criterion) |
|---|---|---|---|---|---|---|---|---|---|
| Hedelin H (18) | 2012 | 61 | 46±11 | NIH-CPSI, CSQ, UPOINT | 11±11 years | 22.8±7.7 | 15.30±9.10 (CSQ) | NA | 17 (28%) (CSQ ≥20) |
| Samplaski MK (19) | 2012 | 220b | 44.6±13.4 | NIH-CPSI, UPOINT | 57.05±87.49 months | 25.02±6.49 | NA | 83 (33.7%)c | 25 (25%)d (NA) |
| Hedelin HH (20) | 2009 | 50 | 46 [26–71] | NIH-CPSI, CSQ, UPOINT | 7 years (6 months – 35 years)e | 23±7 | 16.09±9.5 (CSQ) | 18 (36%) | 15 (30%) (CSQ ≥21) |
| Polackwich AS (21) | 2015 | 82 | 41.6±13.2 | NIH-CPSI, UPOINT | 24 [3–240] months | 26.8±6.3 | NA | 39 (47.60%) | NA |
| Shoskes DA (7) | 2010 | 100 | 46 [18–71] | NIH-CPSI, UPOINT | 24 [3–380] months | 25.2±6.1 | NA | 37 (37%) | NA |
| Zhang YD (22) | 2016 | 192 | 31.3 [18–57] | NIH-CPSI, PCS, UPOINT | 20.5 [3–165] months | 20.5±6.9 | 11.10±10.70 (PCS) | 115 (59.90%) | NA |
| Davis SNP (23) | 2013 | 171 | 44.2±14.0 [18–82] | NIH-CPSI, PCS, UPOINT | 56.7±24 months | 24.1±7.24 | 23.30+12.40 (PCS) | NA | NA |
| Krsmanovic A (2) | 2014 | 175 | 46.83±10.86 | NIH-CPSI, PCS | At least 3 of the last 6 months | 16.47±8.67 | 16.30±9.52 (PCS) | NA | NA |
| Naliboff BD (24) | 2017 | 176 | 47.7±15.5 | NIH-CPSI, PCS, CSQ | 8.1±10.9 years | NA | 50.0±9.10 (PCS), 10.4±8.5 (CSQ) | NA | NA |
| Klotz SGR (25) | 2018 | 81 | 48.33±15.28 | NIH-CPSI, PCS | 6.13±8.69 years | 24.97±7.47 | 23.44±12.93 (PCS) | NA | NA |
a, according to UPOINT; b, 120 patients were characterized by UPOINT and 100 patients were characterized by its subdomain; c, among the all the patients [220]; d, among the 100 patients characterized by the subdomain of UPOINT; e, 20% had a history of less than 1 year. NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom Index; CSQ, Coping Strategies Questionnaire; PCS, Pain Catastrophizing Scale.